Overcoming inequalities: The Affordable Care Act and cancer treatment

Virtual Mentor

Volumn 15, Issue 8, 2013, Pages 692-696

  Gusmano, Michael K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPARATIVE EFFECTIVENESS; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INSURANCE; LEGISLATION AND JURISPRUDENCE; NEOPLASMS;

COMPARATIVE EFFECTIVENESS RESEARCH; HEALTHCARE DISPARITIES; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; NEOPLASMS; PATIENT PROTECTION AND AFFORDABLE CARE ACT;

EID: 84897358400     PISSN: 19377010     EISSN: None     Source Type: Journal    
DOI: 10.1001/virtualmentor.2013.15.8.pfor1-1308     Document Type: Review

References (15)

1. US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716-726.
2. Institute of Medicine Roundtable on Evidence-Based Medicine. Learning What Works Best: The Nation’s Need for Evidence on Comparative Effectiveness in Health Care. Washington, DC: Institute of Medicine; 2007.
3. Gusmano MK, Gray BH. Evidence and fear: navigating the politics of evidence based medicine. AcademyHealth Reports, June 2010: 1. http://www.academyhealth.org/files/publications/academyhealthreports/evidenceandfear.pdf. Accessed June 26, 2013.
4. Duran-Zaleski I. [Economic evaluation of radiotherapy: methods and results]. J Cancer Radiother. 2005;9(6-7):449-451.
5. Karnon J, Jones T. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy for advanced breast cancer in postmenopausal patients. Pharmacoeconomics. 2003;21(7):513-525.
6. Fagnani F, Colin X, Arveux P, Coudert B, Misset JL. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer]. Bull Cancer. 2007;94(7):711-720.
7. McKeage K, Lyseng-Williamson KA. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics. 2008;26(8):699-719.
8. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58(1):9-31.
9. Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9(3):222-231.
10. Nolte E, McKee M. Does health care save lives? Avoidable mortality revisited. London, The Nuffield Trust; 2004. http://www.nuffieldtrust.org.uk/sites/files/nuffield/publication/doeshealthcare-save-lives-mar04.pdf. Accessed June 26, 2013.
11. Weisz D, Gusmano MK, Rodwin VG, Neuberg L. Population health and the health system: a comparative analysis of avoidable mortality in three nations and their world cities. Eur J Pub Health. 2008:18(2):166-172.
12. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast cancer screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ. 2007;321(7262):665-669.
13. Gusmano MK, Rodwin VG, Weisz D. Health Care in World Cities: New York, Paris, and London. Baltimore, MD: Johns Hopkins University Press; 2010.
14. Gusmano MK. NFIB vs Sebelius: the political expediency of the Roberts Court. Health Econ Policy Law. 2013;8(1):119-124.
15. Corlette S, Lucia KW, Levin M. Implementing the Affordable Care Act: choosing an essential health benefits benchmark plan. New York: The Commonwealth Fund; 2013. http://www.commonwealthfund.org/~/media/Files/Publications/Issue%20Bri ef/2013/Mar/1677_Corlette_implementing_ACA_choosing_essential_hlt_be nefits_reform_brief.pdf. Accessed June 26, 2013.